BRIEF-Beigene Provides Update On The Ociperlimab (Bgb-A1217) Clinical Development Program

, Reuters -  6:58 AM ET 4/3/2025 default

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

April 3 (Reuters) - Beigene Ltd:

* BEIGENE PROVIDES UPDATE ON THE OCIPERLIMAB (BGB-A1217) CLINICAL DEVELOPMENT PROGRAM

* BEIGENE LTD - TO DISCONTINUE CLINICAL DEVELOPMENT OF OCIPERLIMAB FOR LUNG CANCER

* BEIGENE LTD - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS TERMINATION OF PHASE 3 ADVANTIG-302 TRIAL

* BEIGENE LTD - STUDY UNLIKELY TO MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL Source text: Further company coverage:

(c) Reuters 2025. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.